Who asks about tesamorelin and what they want to understand

Tesamorelin searches usually start with one of two questions: what is it, and is it the same as the drug prescribed for HIV patients.

TL;DR

• Tesamorelin is a GHRH analog — a synthetic molecule that mimics the hormone that triggers growth hormone release.
• It is FDA-approved as Egrifta for a specific HIV-related condition; off-label use for visceral fat reduction is studied but not FDA-approved.
• People searching for it are typically researching belly fat that has not responded to standard interventions.

What tesamorelin is

Tesamorelin is a synthetic GHRH analog. GHRH (growth hormone releasing hormone — the body’s natural signal to the pituitary to release GH) degrades quickly in the bloodstream. Tesamorelin is a stabilized version designed to last longer and act more consistently.

FDA approved it in 2010 under the brand name Egrifta for adults with HIV-associated lipodystrophy (in plain English: the abnormal fat redistribution that occurs in some people on HIV treatment). That approval is based on multiple controlled clinical trials (FDA label, 2010).

Compounded tesamorelin is not FDA-approved. It is prescribed off-label by clinicians who use the same active ingredient through state-licensed 503A pharmacies.

How it works

Think of the growth hormone axis like a two-step relay race. The hypothalamus fires the starting gun with GHRH. The pituitary runs the next leg and releases GH. Tesamorelin is a synthetic starter pistol — it fires the same signal without depending on the body’s own GHRH supply, which declines with age and stress. The result is a more consistent GH pulse.

Who asks about tesamorelin

People come to this topic from two directions. Some are adults — often men between 40 and 60 — who have read about the clinical trials showing reductions in visceral fat and are curious whether a clinician can prescribe it off-label. Others encounter the name while researching HIV medications and want to understand whether it has any application outside that context.

The common thread is visceral fat (the fat that sits deep inside the abdomen, around the organs). It is particularly resistant to diet and cardio. People searching for tesamorelin have often already tried both.

What the research says

Published randomized controlled trials in HIV-positive adults showed significant reductions in visceral adipose tissue with tesamorelin compared with placebo (Falutz et al., New England Journal of Medicine, 2010, via PMC). About 9 in 10 participants responded. In healthy adults without HIV, smaller off-label studies show GH axis stimulation, but large-scale visceral fat trials in the general population are limited.

What to know before considering it

Tesamorelin requires a prescription. Off-label prescribing is at clinician discretion and should follow a review of IGF-1 levels, metabolic history, and relevant contraindications including active malignancy. Compounded versions are not FDA-approved. Common side effects in trials included edema and joint discomfort in some participants.

The Halftime POV

Tesamorelin is one of the more evidence-backed tools for addressing GH axis function in adults with specific clinical profiles. At Halftime Health, it enters the picture after a full metabolic and hormonal evaluation — not as a first response to a search result.

Related reading:

• Tesamorelin: from HIV lipodystrophy to visceral fat research
• Who asks about CJC-1295
• Sarcopenia prevention for men over 50
• The growth hormone axis explained
• Fatigue in men over 40: a hormonal map

FAQ

Q: What is tesamorelin used for? A: Tesamorelin is a GHRH analog (in plain English: a synthetic version of the hormone that tells the pituitary to release growth hormone). It is FDA-approved as Egrifta for HIV-associated lipodystrophy and is studied off-label for visceral fat in adults without HIV. Compounded tesamorelin is not FDA-approved.

Q: Who asks about tesamorelin? A: People who search for tesamorelin are often adults — frequently men in their late thirties to fifties — researching options for stubborn visceral belly fat that has not responded to diet and exercise. They have usually already read about GLP-1 medications and are looking for alternatives or additions.

Q: Is tesamorelin the same as Egrifta? A: Egrifta is the FDA-approved brand-name version of tesamorelin. Compounded tesamorelin is prepared by 503A pharmacies from the same active ingredient but is not itself FDA-approved and is prescribed off-label.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• Falutz J et al. — Tesamorelin for visceral fat in HIV — NEJM/PMC, 2010
• Egrifta FDA label, 2010